INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation

FRA:IUI1 • US46120E6023

422.35 EUR
+1.5 (+0.36%)
Last: Mar 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

Taking everything into account, IUI1 scores 7 out of 10 in our fundamental rating. IUI1 was compared to 65 industry peers in the Health Care Equipment & Supplies industry. IUI1 gets an excellent profitability rating and is at the same time showing great financial health properties. IUI1 is valued quite expensively, but it does show have an excellent growth rating. With these ratings, IUI1 could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

9

1. IUI1.DE Profitability Analysis

1.1 Basic Checks

  • IUI1 had positive earnings in the past year.
  • In the past year IUI1 had a positive cash flow from operations.
  • IUI1 had positive earnings in each of the past 5 years.
  • IUI1 had a positive operating cash flow in each of the past 5 years.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • IUI1 has a Return On Assets of 13.96%. This is amongst the best in the industry. IUI1 outperforms 95.38% of its industry peers.
  • With an excellent Return On Equity value of 16.02%, IUI1 belongs to the best of the industry, outperforming 87.69% of the companies in the same industry.
  • The Return On Invested Capital of IUI1 (13.95%) is better than 89.23% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for IUI1 is in line with the industry average of 10.72%.
  • The 3 year average ROIC (12.43%) for IUI1 is below the current ROIC(13.95%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROIC 13.95%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • IUI1 has a Profit Margin of 28.38%. This is amongst the best in the industry. IUI1 outperforms 100.00% of its industry peers.
  • IUI1's Profit Margin has improved in the last couple of years.
  • IUI1 has a Operating Margin of 29.35%. This is amongst the best in the industry. IUI1 outperforms 96.92% of its industry peers.
  • In the last couple of years the Operating Margin of IUI1 has grown nicely.
  • IUI1's Gross Margin of 66.00% is fine compared to the rest of the industry. IUI1 outperforms 73.85% of its industry peers.
  • IUI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 29.35%
PM (TTM) 28.38%
GM 66%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IUI1.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
  • IUI1 has less shares outstanding than it did 1 year ago.
  • IUI1 has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

2.2 Solvency

  • IUI1 has an Altman-Z score of 41.46. This indicates that IUI1 is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of IUI1 (41.46) is better than 100.00% of its industry peers.
  • There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 41.46
ROIC/WACC1.4
WACC9.95%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 4.87 indicates that IUI1 has no problem at all paying its short term obligations.
  • IUI1 has a Current ratio of 4.87. This is amongst the best in the industry. IUI1 outperforms 96.92% of its industry peers.
  • A Quick Ratio of 3.96 indicates that IUI1 has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.96, IUI1 belongs to the top of the industry, outperforming 96.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 3.96
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. IUI1.DE Growth Analysis

3.1 Past

  • IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.83%, which is quite impressive.
  • IUI1 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 21.42% yearly.
  • Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 20.51%.
  • IUI1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.22% yearly.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%

3.2 Future

  • IUI1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.58% yearly.
  • IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.90% yearly.
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

1

4. IUI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 54.78 indicates a quite expensive valuation of IUI1.
  • Compared to the rest of the industry, the Price/Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 61.54% of the companies listed in the same industry.
  • IUI1 is valuated expensively when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 47.86 indicates a quite expensive valuation of IUI1.
  • Based on the Price/Forward Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 69.23% of the companies are valued more cheaply.
  • The average S&P500 Price/Forward Earnings ratio is at 24.27. IUI1 is valued rather expensively when compared to this.
Industry RankSector Rank
PE 54.78
Fwd PE 47.86
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 67.69% of the companies in the same industry are cheaper than IUI1, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, IUI1 is valued a bit more expensive than 60.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 69.74
EV/EBITDA 45.44
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of IUI1 may justify a higher PE ratio.
  • A more expensive valuation may be justified as IUI1's earnings are expected to grow with 14.52% in the coming years.
PEG (NY)3.79
PEG (5Y)2.56
EPS Next 2Y14.34%
EPS Next 3Y14.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IUI1.DE Dividend Analysis

5.1 Amount

  • IUI1 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IUI1.DE Fundamentals: All Metrics, Ratios and Statistics

INTUITIVE SURGICAL INC

FRA:IUI1 (3/11/2026, 7:00:00 PM)

422.35

+1.5 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22
Earnings (Next)04-20
Inst Owners88.53%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap149.99B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts78.1
Price Target527.49 (24.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)-1.16%
PT rev (3m)0.59%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)0.27%
EPS NY rev (1m)0%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)1.02%
Valuation
Industry RankSector Rank
PE 54.78
Fwd PE 47.86
P/S 17.26
P/FCF 69.74
P/OCF 57.32
P/B 9.75
P/tB 9.96
EV/EBITDA 45.44
EPS(TTM)7.71
EY1.83%
EPS(NY)8.83
Fwd EY2.09%
FCF(TTM)6.06
FCFY1.43%
OCF(TTM)7.37
OCFY1.74%
SpS24.47
BVpS43.34
TBVpS42.4
PEG (NY)3.79
PEG (5Y)2.56
Graham Number86.71
Profitability
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROCE 16.01%
ROIC 13.95%
ROICexc 20.73%
ROICexgc 21.4%
OM 29.35%
PM (TTM) 28.38%
GM 66%
FCFM 24.75%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 79.72%
Cap/Sales 5.36%
Interest Coverage 250
Cash Conversion 83.46%
Profit Quality 87.21%
Current Ratio 4.87
Quick Ratio 3.96
Altman-Z 41.46
F-Score8
WACC9.95%
ROIC/WACC1.4
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.56%
EBIT Next 3Y21.57%
EBIT Next 5Y17.26%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%

INTUITIVE SURGICAL INC / IUI1.DE FAQ

Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?

ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.


Can you provide the valuation status for INTUITIVE SURGICAL INC?

ChartMill assigns a valuation rating of 1 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.


Can you provide the profitability details for INTUITIVE SURGICAL INC?

INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.


Can you provide the financial health for IUI1 stock?

The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.